一项开放标签、单组研究,评估皮下注射 Sonelokimab 在中度至重度化脓性汗腺炎青少年中的药代动力学和安全性 (VELA-TEEN)
一项开放标签、单臂研究,旨在评估皮下注射 Sonelokimab 在研究时年龄≥12岁至≤17岁青少年中的药代动力学和安全性,其中包括活动性中度至重度化脓性汗腺炎
This is a study to evaluate the pharmacokinetic (PK) and safety of sonelokimab in adolescent patients with HS.
研究概览
研究类型
注册 (实际的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
Arkansas
-
North Little Rock、Arkansas、美国、72117
- Clinical Site
-
-
California
-
Stanford、California、美国、94304
- Clinical Site
-
-
District of Columbia
-
Washington D.C.、District of Columbia、美国、20010
- Clinical Site
-
-
Florida
-
Hollywood、Florida、美国、33201
- Clinical Site
-
Miami、Florida、美国、33136
- Clinical Site
-
-
Georgia
-
Macon、Georgia、美国、31217
- Clinical Site
-
Sandy Springs、Georgia、美国、30328
- Clinical Site
-
-
Illinois
-
Chicago、Illinois、美国、60611
- Clinical Site
-
-
Indiana
-
Columbus、Indiana、美国、47201
- Clinical Site
-
-
Kentucky
-
Murray、Kentucky、美国、42071
- Clinical Site
-
-
Michigan
-
Waterford、Michigan、美国、48328
- Clinical Site
-
-
North Dakota
-
Fargo、North Dakota、美国、58103
- Clinical Site
-
-
South Carolina
-
Charleston、South Carolina、美国、29425
- Clinical Site
-
-
Texas
-
Dallas、Texas、美国、75246
- Clinical Site
-
Dallas、Texas、美国、75390-8575
- Clinical Site
-
San Antonio、Texas、美国、78218
- Clinical Site
-
-
Virginia
-
Norfolk、Virginia、美国、23502
- Clinical Site
-
-
Washington
-
Seattle、Washington、美国、98105
- Clinical Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Participants must be between ≥12 and ≤17 years of age at the time of signing the informed consent.
- Participants who are diagnosed with HS as determined by the investigator and have a history of signs and symptoms of HS for ≥6 months before signing the informed consent.
- Participants who have moderate to severe HS as determined by the refined Hurley staging (Stages IB and IC, IIB and IIC, and III).
- Participants who have had an inadequate response to appropriate systemic antibiotics for treatment of HS .
- Participants must be up to date with age-appropriate vaccine requirements 8 weeks prior to entry in the study.
- Participants with a body weight of ≥ 40 kg.
Exclusion Criteria:
- Participants with a known hypersensitivity to sonelokimab or any of its excipients.
- Participants with a draining fistula count of ≥20 at the Screening Visit.
- Participants with any other active skin disease or condition that may, in the opinion of the investigator, interfere with the assessment of HS.
- Participants with underlying conditions that, in the opinion of the investigator, potentially compromise the participant and/or places the participant at unacceptable risk.
- Participants who have history or concurrent clinically significant medical conditions or any other reason, including any physical, psychological, or psychiatric condition, that in the opinion of the investigator would compromise the safety or interfere with participation in the study, would make the participant an unsuitable candidate to receive study drug, or would put the participant at risk.
- Participants with any other skin disease or other medical condition that in the opinion of the investigator would interfere with an accurate assessment of clinical symptoms of HS.
- Participants with a confirmed or suspected diagnosis of inflammatory bowel disease.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:sonelokimab
Subjects will receive sonelokimab 120mg subcutaneously (SC) as an induction regimen of 4 doses, followed by sonelokimab SC every 4 weeks maintenance dose starting at Week 8 |
Open label |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Pharmacokinetics (PK) of sonelokimab in adolescents
大体时间:Week 24
|
PK (trough concentrations) of sonelokimab over 24 weeks of treatment |
Week 24
|
|
Adverse events (AEs) following treatment with sonelokimab in adolescents
大体时间:Week 24
|
Incidence, relatedness, severity and seriousness of all AEs over 24 weeks of treatment from baseline |
Week 24
|
|
Discontinuation of sonelokimab treatment due to AEs
大体时间:Week 24
|
Number of participants discontinued from sonelokimab treatment due to AE over 24 weeks of treatment from baseline |
Week 24
|
|
Clinically significant changes in clinical laboratory parameters
大体时间:Week 24
|
Number of participants with clinically significant changes in hematology, biochemistry and urinalysis from baseline |
Week 24
|
|
Clinically significant changes in vital signs
大体时间:Week 24
|
Number of participants with clinically significant changes in vital signs from baseline |
Week 24
|
|
Clinically significant changes in standard 12-lead electrocardiogram (ECG) intervals
大体时间:Week 24
|
Number of participants with clinically significant changes in 12-lead ECG intervals from baseline |
Week 24
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Hidradenitis Suppurativa Clinical Response (HiSCR)75
大体时间:Week 24
|
Percentage of participants achieving a HiSCR75 response over time |
Week 24
|
|
Hidradenitis Suppurativa Clinical Response (HiSCR) 50
大体时间:Week 24
|
Percentage of participants achieving a HiSCR50 response over time |
Week 24
|
|
International Hidradenitis Suppurativa Severity Score System (IHS4)
大体时间:Week 24
|
Absolute change in IHS4 score over time |
Week 24
|
|
Children's Dermatology Life Quality Index (CDLQI)
大体时间:Week 24
|
Percentage of participants achieving a CDLQI total reduction of ≥2.5 over time among participants with a baseline CDLQI ≥2.5 |
Week 24
|
|
Numerical Rating Scale (NRS) 30
大体时间:Week 24
|
Percentage of participants achieving a ≥30% reduction and a ≥2-unit reduction over time in the NRS30 for pain in PGA among participants with a baseline NRS ≥3 |
Week 24
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.